Analysts are intrested in these 5 stocks: ( (NDAQ) ), ( (IONQ) ), ( (OPK) ), ( (EXAS) ) and ( (PANW) ). Here is a breakdown of their recent ratings and the rationale behind them.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Nasdaq’s stock is catching the eyes of investors as analyst Michael Cyprys upgrades it to a ‘Buy’ with a price target of $110. The recommendation is based on the expected acceleration in revenue growth across its Solutions business, driven by a recovering capital market and a supportive macroeconomic environment. The transformation of Nasdaq’s business model is anticipated to lead to higher quality revenue streams, making it an attractive option for investors looking for growth opportunities.
IonQ is making waves in the quantum computing space, with analyst Peter Peng initiating coverage with a ‘Hold’ rating and a price target of $47. IonQ’s early mover advantage in disruptive quantum technology positions it well for future growth. The company is developing a comprehensive full-stack platform that integrates hardware, software, and ecosystem development, similar to Nvidia’s approach. Despite the promising technology and business outlook, the current valuation reflects a balanced risk/reward scenario, leading to a neutral stance.
Opko Health is in the spotlight as analyst Brian Cheng initiates coverage with a ‘Hold’ rating. The company is transitioning its focus towards its therapeutics pipeline, following the sale of select BioReference assets. While the core lab services are moving towards profitability, the therapeutic side, through ModeX, remains in early stages and requires clinical validation. Investors are advised to stay on the sidelines as the company works towards achieving profitability and clinical validation for its pipeline.
Exact Sciences has been downgraded to ‘Hold’ by multiple analysts following Abbott’s announcement to acquire the company for $23 billion. The acquisition, expected to close in Q2 2026, offers a significant premium to Exact Sciences’ stock price. While the deal is seen as a strategic move for Abbott, the limited upside potential at current levels leads to a neutral rating. Investors are advised to consider other opportunities in the diagnostics space as Exact Sciences transitions under Abbott’s ownership.
Palo Alto Networks faces a downgrade to ‘Sell’ by analyst Stephen Bersey, with a price target of $157. Despite a strong performance in its latest earnings report and continued traction in its software firewalls, the long-term revenue growth appears to be decelerating. The market’s high valuation of Palo Alto Networks, coupled with limited scope for estimate upgrades, suggests a negative risk/reward profile. Investors are cautioned about the potential for a negative re-rating of the stock.